Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,518 across all filing types
Latest filing 2024-04-24 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the purchase of shares on the market pursuant to its share award scheme. It details the number of shares purchased, the average price, and the balance held by the trustee. There is no financial report, earnings data, or management discussion. The document is an announcement about share repurchase activity related to a share award scheme, which fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2024-04-24 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Transaction in Own Shares Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the purchase of shares on the market pursuant to a share award scheme. It details the number of shares purchased, the average price, and the total consideration. The document is short (2316 characters) and is an announcement of a share purchase related to the company's share award scheme, not a financial report or earnings release. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or share purchases for schemes. There is no indication that this is a full financial report, regulatory filing, or other categories like capital update or director dealings. Therefore, the correct classification is POS with high confidence.
2024-04-23 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the three months ended 31 March 2024. It references the quarterly report published by CSPC Innovation on the Shenzhen Stock Exchange website and provides detailed financial data such as revenue, net profit, cash flows, and explanations for significant changes in accounting data and financial indicators. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly period). It is not merely an announcement of a report publication but includes actual financial figures and explanations. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-22 English
NEXT DAY DISCLOSURES RETURNS
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It details repurchases of shares on specific dates, quantities, prices, and confirms compliance with listing rules. The content is a regulatory disclosure about share repurchases, not a full financial report or earnings release. It is a formal notification of transactions in own shares, consistent with share buyback reporting requirements. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail support this classification with high confidence.
2024-04-22 English
GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the grant of share awards under its share award scheme. It details the number of shares granted, the vesting date, the absence of performance targets, and the clawback/lapse mechanisms. The announcement also discusses compliance with listing rules and the purpose of the grant. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is relatively short (4331 characters) and serves as a notification of a share award grant, which is a capital-related event but not a full capital change announcement like a new share issue or stock split. It is not a report or presentation but an official announcement of a share award grant under the company's employee incentive scheme. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes including share awards and grants.
2024-04-22 English
NEXT DAY DISCLOSURES RETURNS
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules. The document references specific listing rules from the Stock Exchange of Hong Kong and provides transactional details of share repurchases. This type of document is a regulatory disclosure about share capital changes and share buybacks, not a full financial report or earnings release. It fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2024-04-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.